(18.97.9.170)
[ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2021, Volume : 14, Issue : 5
First page : ( 2643) Last page : ( 2648)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.52711/0974-360X.2021.00466

Ineffective drugs: Cerebrolysin and piracetam

Slyusar Olga1,*, Maximov Ivan2, Babaskina Liudmila3, Lobuteva Liudmila4

1Department of Pharmacy, Private Institution Educational Organization of Higher Education Medical University “Reaviz”, Moscow, Russian Federation

2Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation

3Department of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation

4Department of Pharmacy Organization and Economics, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation

*Corresponding Author E-mail: ol.slyusar@rambler.ru

Online published on 25 August, 2021.

Abstract

The study of drug efficacy is greatly importance, since the data obtained can be used as a scientific tool for reevaluating drugs. The aim of the study is to evaluate the efficacy of cerebrolysin and piracetam in patients with acute ischemic stroke. The study included 124 patients with moderate acute ischemic stroke (AIS). All patients were divided into two experimental groups and one control group. The control group included 40 people receiving standard therapy (acetylsalicylic acid, lisinopril, nebivolol, pentoxifylline, L-lysine escinate). The cerebrolysin group consisted of 42 patients who additionally received cerebrolysin (10ml) in a volume of 200ml (0.9% NaCl) once a day. The piracetam group included 42 patients who additionally received piracetam (10ml) in a volume of 200ml (0.9% NaCl) three times a day. The course of inpatient treatment lasted 3 weeks. At the end of treatment, there was a significant (p <0.05) regression of neurological symptoms in patients with acute ischemic stroke in all comparison groups by 1.75 (p <0.05) times in the control group, by 1.85 (p < 0.05) in the cerebrolysin group and by 1.78 (p <0.05) in the piracetam group. There was no statistically significant intergroup difference (p> 0.05). The study results do not demonstrate clinical benefits of cerebrolysin and piracetam for treating acute ischemic stroke.

Top

Keywords

Acute ischemic stroke, Neuroprotective agents in stroke treatment, Cerebrolysin in stroke, Piracetam in stroke, Rational pharmacotherapy, Drug efficacy and safety, Therapeutic efficacy of cerebrolysin and piracetam.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
905,592,696 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.